![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 27, 2026
The latest clinical trial findings in breast cancer, leukemia, lymphoma, lung cancer, NCI-MATCH, and prostate cancer
December 19, 2025
The trials explore potential treatment improvements for different cancer types: bladder, lung, lymphoma, myeloma, and stomach
December 19, 2025
Blood and breast cancer research highlights from the 67th American Society of Hematology Annual Meeting and Exposition, and the San Antonio Breast Cancer Symposium
November 21, 2025
The latest clinical trial findings in follicular lymphoma, prostate cancer, precision medicine, symptom science, and patient -reported outcomes
June 11, 2025
The changes broaden eligibility and clarify treatment planning details in this phase 2 trial testing daratumumab-hyaluronidase to eliminate minimal residual disease after initial chemotherapy
April 24, 2025
These two trials are open and enrolling adolescent and young adult survivors and patients with cancer
March 21, 2025
Summaries of recently published ECOG-ACRIN and PrECOG research results
February 19, 2025
This is the first randomized phase 3 study to evaluate autologous stem cell transplantation in patients with this rare and aggressive form of non-Hodgkin lymphoma
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
June 25, 2025
This clinical trial is evaluating a new drug combination for patients with B-cell lymphoma that has relapsed after remission or no longer responds to standard treatment
December 23, 2024
Summaries of presentations at the 2024 San Antonio Breast Cancer Symposium as well as the 66th American Society of Hematology Annual Meeting and Exposition in San Diego
November 25, 2024
